Background: Urinary incontinence (UI), a common malady in women, most often is classified as stress, urgency, or mixed.
U
rinary incontinence (UI), the involuntary loss of urine, affects about 17% of nonpregnant women (1) , and its prevalence increases with age, particularly after menopause. Incontinence may have a negative effect on a woman's physical, psychological, and social well-being and may impose substantial lifestyle restrictions. The most common types of UI in women are stress, urgency, and mixed incontinence. Stress UI is the involuntary loss of urine with effort or physical exertion or on sneezing or coughing, urgency UI is associated with a sudden compulsion to urinate that is difficult to defer, and mixed UI has features of both types (2) .
Nonpharmacologic and pharmacologic interventions are available to manage UI. Nonpharmacologic approaches mostly aim to strengthen the pelvic floor or change behaviors that influence bladder function, whereas pharmacologic treatments primarily address bladder and urethral sphincter function.
We conducted a broad systematic review of the clinical effects and harms of all nonsurgical treatments for stress, urgency, and mixed UI in nonpregnant women. Although some causes of UI are amenable to
Study Selection
We included studies of adult women with stress, urgency, or mixed UI, excluding those who were pregnant, hospitalized, or institutionalized and those with UI due to urinary tract infection or neurogenic bladder; however, we allowed up to 10% of study participants to fall into any of the exclusion categories. We included comparisons of pharmacologic, nonpharmacologic (nonsurgical), and placebo (or sham or no) treatments for stress, urgency, or mixed UI. Among eligible interventions, we included those that sometimes require minor surgery (such as device implantation for sacral neuromodulation) or might be performed in an office setting (such as periurethral bulking and bladder onabotulinum toxin A [BTX] injection).
Studies had to report categorical symptomatic cure (for example, cured vs. not cured), improvement, or satisfaction after treatment; quality-of-life score after treatment; or adverse events related to treatment. This article focuses on the clinical outcomes of cure and improvement. As commonly understood, symptomatic "cure" means resolution of incontinence; it does not imply permanent cure.
We included RCTs with no minimum sample size and nonrandomized comparative studies with at least 50 women per intervention group. All studies had to have a minimum follow-up of 4 weeks. We included only peer-reviewed publications and studies with complete results data in ClinicalTrials.gov or available from the U.S. Food and Drug Administration. We included translatable studies in any language. Four studies, 2 in Russian and 2 in Persian, could not be translated and were excluded. The non-English studies included were published in Spanish (2 studies), French (1 study), and Chinese (1 study).
Data Extraction and Quality Assessment
Each new study was extracted and assessed for methodological quality by 1 methodologist. The extraction and assessment were reviewed and confirmed by at least 1 other experienced methodologist. Disagreements were resolved by discussion among the team members. Studies were extracted into a customized form in the Systematic Review Data Repository (https: //srdr.ahrq.gov/projects/1153). To assess quality, we used the Cochrane Risk of Bias Tool for RCTs (6) . For nonrandomized comparative studies, we evaluated outcome assessor blinding; attrition bias; group similarity at baseline; adherence; and whether groups were selected similarly, analyses were adjusted for differences between groups, and interventions were described adequately.
We graded strength of evidence (SoE) according to the AHRQ methods guide (7) . We assessed SoE for each outcome category for our main conclusion statements across all intervention categories. For each SoE assessment, we considered the number of studies, study designs, study limitations (that is, risk of bias and overall methodological quality), directness of the comparisons (in the network), consistency of study results, precision of any estimates of effect (imprecise if the 95% CI extended beyond both 0.80 and 1.25), likelihood of reporting bias, other limitations, and overall findings across studies. On the basis of these assessments, we assigned an SoE rating of high, moderate, or low or deemed the evidence insufficient to estimate an effect.
Data Synthesis and Analysis

Categorization of Interventions
Where feasible, we used guidelines from the National Institute for Health and Care Excellence and the American Urological Association to categorize interventions (8, 9) . First, we classified the 53 specific interventions for which there were any outcomes of interest (including adverse events) into 16 categories (Table 1) . Then, we divided the categories further on the basis of whether they are recommended primarily for stress or urgency UI. Behavioral therapy is recommended for both stress and urgency UI and thus appeared in both categories. Neuromodulation is recommended primarily for urgency UI, but several RCTs evaluated it in women with stress UI; thus, it also was included in both categories. Next, we stratified the interventions according to whether they are recommended as first-, second-, or third-line therapies (8, 9) .
Network Meta-analysis
We conducted frequentist (maximum-likelihood) pairwise comparisons and NMAs of odds ratios (ORs) with mixed-effects (random intercepts and fixed intervention slopes) or full random-effects (random intercepts and slopes) multilevel models within the generalized linear and latent mixed modeling framework. We assessed consistency qualitatively, deeming direct and indirect effects in agreement if they were in the same direction and if the CI of one included the point estimate of the other, and quantitatively, using a "nodesplit" approach (10) . Further details are provided in Supplement 1.
We conducted separate sets of NMAs for each UI outcome (cure and improvement). Originally, we considered performing separate NMA sets for each UI type (stress, urgency, and mixed); however, many studies did not restrict their eligibility to women with a specific UI type, and very few studies reported specifically on women with mixed UI. Therefore, for each UI outcome, we ran an overall NMA that included all eligible studies regardless of UI type or line of therapy. Then, we summarized comparisons of interventions on the basis of whether they are used (or recommended) primarily for urgency or stress UI and whether they are first-and second-line therapies or third-line therapies (8, 9) . We ran separate sets of NMAs for specific interventions and for intervention categories.
The analyses are presented in the full report (3) . We ran separate NMAs of the subsets of studies that included only women with stress or urgency UI and compared these results with the overall analyses.
Role of the Funding Source
This topic was nominated and funded by PCORI for systematic review by an Evidence-based Practice Center in partnership with AHRQ. Program officers from AHRQ and PCORI provided comments on draft versions of the protocol and full evidence report (3) . Neither PCORI nor AHRQ participated directly in the literature search; determination of study eligibility criteria; data analysis or interpretation; or preparation, review, or approval of the manuscript for publication.
RESULTS
The 2018 search returned 7840 new citations, 7117 of which were excluded during abstract screening (8, 9) . Placebo/sham/no intervention study groups were included as an additional intervention category. † An x indicates that evidence exists regarding the outcome for the intervention category. Empty cells indicate that the outcome was not reported in studies of the given intervention. ‡ Behavioral therapy is commonly used in both stress and urgency UI. Neuromodulation is most commonly used in urgency UI, but studies have evaluated it in women with stress UI. § No eligible studies evaluated cure or improvement.
( Figure 1 ). Of the 723 abstracts accepted at the initial screening and retrieved for full-text review, 613 were found to be irrelevant, primarily because they did not include our population of interest. Other reasons are listed in Figure 1 . The 110 new studies were combined with the 134 articles from the original report that met the eligibility criteria. Of these, 84 reported cure (52 studies in 51 articles ) or improvement (64 studies in 63 articles ). The updated search in August 2018 revealed no new eligible trials. Of the 16 intervention categories, 2 (antiepileptics and ␤-adrenergic agonists) were not evaluated for cure or improvement by eligible studies. As described in Table 1 , several intervention categories include several specific treatments. In particular, behavioral therapy is a broad category that focuses mainly on bladder training (learning to gradually hold urine for longer periods) and muscle strengthening. Neuromodulation includes both electrical and magnetic stimulation. Hormones include estrogen and raloxifene delivered via various routes. Anticholinergics include 11 specific drugs. The NMAs that evaluated the 51 specific treatments (3) yielded similar but more complex conclusions than the analysis of intervention categories presented here. For example, comparison of 11 behavioral therapies (including combinations of behavioral therapies) found a statistically significant difference only between the combination of pelvic floor muscle therapy and biofeedback versus education, favoring the former. Across studies and outcomes, risk of bias was low or moderate in about 85% of studies (Appendix Figure, available at Annals.org). The most common concerns were a lack of participant or outcome assessor blinding and high attrition rates. Studies commonly did not report on allocation concealment and blinding.
For either cure or improvement, the trials provided direct evidence from 30 of 91 possible comparisons among the 14 evaluable intervention categories (including no treatment); 18 of the 30 were comparisons between active interventions, and 12 compared active interventions with no treatment. Figures 2 and 3 
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Urinary Incontinence Nonsurgical Treatments: Cure and Improvement only women with stress UI, 16 (19%) only those with urgency UI, and 4 (5%) those with mixed UI. The remaining 32 studies (38%) included women with any UI type or did not specify type. Unless otherwise noted, ORs refer to the overall NMA (with all studies, regardless of UI type) and findings from the NMA restricted to studies of women with either stress or urgency UI were similar (although usually less precise). Imprecise, statistically nonsignificant effect sizes were omitted from the main text and tables, but are reported in Supplement 3 (available at Annals .org). The full report includes other analyses, whose conclusions were concordant with those reported here (3). Study-level data are available in the Systematic Review Data Repository (available at www.srdr.ahrq.gov /projects/1153). An evidence profile summarizing the SoE for each finding is presented in Supplement 4 (available at Annals.org).
Stress UI
Among first-and second-line interventions for stress UI, behavioral therapy (alone and combined with hormones) was more effective than either ␣-agonists or hormones in achieving cure or improvement (moderate SoE); ␣-agonists were more effective than hormones in bringing about improvement (moderate SoE).
Among third-line interventions evaluated for stress UI, intravesical pressure release (IVPR) and neuromodulation, but not periurethral bulking agents, were more effective than hormones or no treatment in achieving cure or improvement (variable SoE). Indirect evidence suggests that IVPR is more effective than neuromodulation combined with behavioral therapy or hormones in bringing about improvement but that behavioral therapy may be more effective than either periurethral bulking or combination neuromodulation and behavioral therapy (all low SoE).
Cure
First-and Second-Line Interventions. The first-and second-line interventions evaluated for stress UI cure were behavioral therapy, ␣-agonists, hormones, and hormones plus behavioral therapy ( Table 2 ). There is Third-Line Interventions. Third-line therapies evaluated for stress UI improvement included IVPR, periurethral bulking agents, neuromodulation, and combinations of neuromodulation with behavioral therapy and with both behavioral therapy and hormones ( (38) .
No study directly compared third-line interventions. Among the studies enrolling only women with stress UI, neuromodulation plus hormones plus behavioral therapy may have been better than periurethral bulking agents in effecting improvement (OR, 5.92 [CI, 0.95 to 37.0]), on the basis of low SoE; across all studies, a similar but imprecise finding was observed. Also with low SoE, IVPR may have been more likely than neuromodulation plus behavioral therapy to result in improvement (OR, 4.41 [CI, 0.93 to 20.9]) among studies of stress UI only; across all studies, a smaller, imprecise effect was found. The analyses evaluating neuromodulation plus behavioral therapy with versus without addi- tional hormones were inconsistent, with the NMA of the stress UI-only studies suggesting a large benefit from triple versus double therapy ( Table 3) .
Urgency UI
Among the treatments used as first-or second-line interventions for urgency UI, behavioral therapy was statistically significantly more effective than anticholinergics in achieving cure or improvement (high SoE).
Among the third-line treatments for urgency UI, both neuromodulation and BTX were more effective than no treatment (high SoE), and BTX may have been more effective than neuromodulation in achieving cure (low SoE). There is high SoE that behavioral therapy was more effective than anticholinergics (OR, 1.83 [CI, 1.04 to 3.23]) across all studies, with a stronger effect seen in studies of urgency UI exclusively. On the basis of urgency UI-only studies, combination therapy with anti- 
DISCUSSION
Evidence supports the use of most approachesnonpharmacologic, pharmacologic, and combinationover no intervention (or, in clinical practice, watchful waiting). The exceptions are hormones and periurethral bulking agents, for which low SoE suggests no difference in relative rates of cure and improvement. However, as described in the full report (3) and summarized in Table 6 , adverse events vary across interventions, which may affect the treatment a woman chooses. Nevertheless, interventions that included behavioral therapy generally were more effective than those that did not.
Overall, the results of our review are consistent with recommendations from 6 international UI guidelines (94) . All guidelines recommend a trial of conservative treatment before more invasive therapies, although some include specific recommendations for conservative treatments that were not identified in our review, such as smoking cessation and caffeine avoidance. Most guidelines recommend the use of anticholinergic and ␤-agonist medications, with opinion-based recommendations regarding particular considerations for use. The European Association of Urology guidelines echo a Cochrane review (95) showing that ␣-agonists are no better than placebo for stress UI; however, we found that ␣-agonists were better than placebo for improving but not curing (that is, fully relieving symptoms from) stress UI. The guidelines and our review support the use of BTX and sacral neuromodulation.
Our findings are consistent with previously published systematic reviews regarding nonsurgical treatment of UI in women but are more complete, because we evaluated additional medication classes and inter- 
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Urinary Incontinence Nonsurgical Treatments: Cure and Improvement ventions, and conducted NMAs to combine direct evidence from head-to-head comparisons with indirect evidence. Thus, we estimated treatment effects for all possible comparisons among intervention categories (and individual interventions). A summary of 20 Cochrane reviews of nonsurgical treatments for UI (96) found that many of the reviews included studies of women with overactive bladder without incontinence as well as those with other pelvic floor muscle disorders. Nevertheless, the findings were similar for specific comparisons of behavioral therapy, neuromodulation, electrostimulation, acupuncture, periurethral bulking agents, and ␣-agonists, mostly versus no treatment. The major gap identified by this review is the relative dearth of direct (head-to-head trial) evidence, considering the richness of the clinical questions that may be posed. Most comparisons between intervention categories were indirect, through sham or no treatment. About 40% of the studies included both women with stress UI and those with urgency UI or did not adequately describe their eligibility criteria. Very few studies based their eligibility criteria on whether patients had received previous treatment (and whether it failed). Also, very few studies described or based eligibility criteria on symptom severity; thus, evaluating subgroup analyses or summarizing across studies on the basis of these descriptors was difficult.
Indirect comparisons rely on the assumption that no influential systematic differences exist in the distribution of effect modifiers in the synthesized studies.
Conceptually, the corpus of studies on UI in women includes heterogeneous samples of women based on UI type, UI severity, and treatment history. The overall NMA makes the same general assumptions as a plurality of studies, namely that the comparative effectiveness of interventions is consistent across different subgroups. Split-node analyses, which compare direct and indirect comparisons, were consistent with a valid network model (Supplement 1).
We followed the lead of current guidelines and previous systematic reviews by grouping the 51 sometimes disparate interventions into broad categories. The categorization was broadest for behavioral therapy ( Table 2) . Analyses of the comparisons among specific interventions within categories found little evidence supporting differences among the specific interventions.
A set of core outcome measures for effectiveness needs to be adopted. More consistent reporting of standard outcomes would have allowed more robust and precise findings. A core outcome set would be most useful if it were based on patient-centered outcomes rather than clinician or researcher priorities.
Information to further clarify whether specific subpopulations might benefit more from particular interventions is still lacking. Studies should either include women with only a specific type of UI (stress, urgency, or mixed) or report subgroup results for all outcomes. They also should report UI severity (for example, frequency or volume) and previous treatments for all participants and, if feasible, provide subgroup results. Second ND ND BTX = onabotulinum toxin A; IVPR = intravesical pressure release; ND = no data; SoE = strength of evidence; UI = urinary incontinence; UTI = urinary tract infection; OEOEOE = high SoE for superiority to other active interventions; OEOE = moderate SoE for superiority to other active interventions; OE = low SoE for superiority to other active interventions; +++ = high SoE for superiority to no intervention; ++ = moderate SoE for superiority to no intervention; + = low SoE for superiority to no intervention; ᭜᭜᭜ = high SoE for inferiority to no intervention (or for adverse events); ᭜᭜ = moderate SoE for inferiority to no intervention (or for adverse events); ᭜ = low SoE for inferiority to no intervention (or for adverse events). * See Table 1 for specific interventions. † Interventions were categorized on the basis of recommendations from the National Institute for Health and Care Excellence and American Urological Association (8, 9) . ‡ Empty fields indicate insufficient evidence (3). § Behavioral therapy is commonly used for both stress and urgency UI. Neuromodulation is most commonly used for urgency UI, but studies have evaluated it in women with stress UI.
Our NMA yielded 4 main conclusions for clinically managing UI. First, most active intervention categories are better than sham or no treatment, with the possible exception of hormones and periurethral bulking agents. Second, behavioral therapy, alone or combined with other interventions, is generally more effective than other first-and second-line monotherapies for both stress and urgency UI. Third, besides being less effective than behavioral therapy, second-line pharmacologic treatments, when used alone, are associated with nonserious but bothersome adverse events, such as dry mouth, nausea, and fatigue. Fourth, the third-line interventions BTX, neuromodulation, and IVPR are generally more effective than other approaches. Large gaps remain in the literature regarding comparisons of individual interventions and subgroup analyses. For clinicians, patients, and payers to make informed decisions, specifically regarding patient subgroups with sparse evidence, new evidence is needed from studies comparing interventions.
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